SCHEMBL24166406

SCHEMBL24166406

CN(C)c1cnc(C=O)s1

nearest known ligand 0.36

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK5 Q00535 1/20 0.36
FFAR2 O15552 1/20 0.34
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP2A6 P11509 1/20 0.30
CYP2A13 Q16696 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25000856 0.77 POLB (0.39) KDM4EALDH1A1
SCHEMBL932978 0.71
SCHEMBL24166743 0.71 CCNE1 (0.37) CCNE1CDK2CDK5FFAR2KDM4E
SCHEMBL28986430 0.71 CCNE1 (0.37) CCNE1CDK2CDK5FFAR2KDM4E
SCHEMBL30276270 0.71 CCNE1 (0.37) CCNE1CDK2CDK5FFAR2KDM4E
SCHEMBL28477655 0.71 CYP2A6 (0.36) KDM4EALDH1A1CYP2A6
SCHEMBL6455262 0.71 CCNE1 (0.36) CCNE1CDK2CDK5FFAR2
SCHEMBL16114009 0.67
SCHEMBL10272882 0.67
SCHEMBL2901458 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368636-A1 NOVEL HETEROCYCLIC COMPOUND, SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2025-12-04 US disclosed
WO-2023238683-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION 国立大学法人電気通信大学 2023-12-14 WO disclosed
US-11807612-B2 Heterocyclic compound and salt thereof, and luminescent substrate composition THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-11-07 US disclosed
US-11807612-B2 Heterocyclic compound and salt thereof, and luminescent substrate composition THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-11-07 US disclosed
US-11807612-B2 Heterocyclic compound and salt thereof, and luminescent substrate composition THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-11-07 US disclosed
US-20230192635-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-06-22 US disclosed
US-20230192635-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-06-22 US disclosed
US-20230192635-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION THE UNIVERSITY OF ELECTRO-COMMUNICATIONS (JP) 2023-06-22 US disclosed
CN-115996914-A Novel heterocyclic compound and salt thereof, and luminescent substrate composition 国立大学法人电气通信大学 2023-04-21 CN disclosed
WO-2022004744-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION 国立大学法人電気通信大学 2022-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11807612-B2 Heterocyclic compound and salt thereof, and luminescent substrate composition RXFP4, NR2E3, ARRB1 CCNE1 1781/4885CDK2 2984/4885CDK5 4463/4885
US-20230192635-A1 NOVEL HETEROCYCLIC COMPOUND AND SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION RXFP4, CRY1, NOX4 CCNE1 1588/4885CDK2 2611/4885CDK5 4355/4885
US-20250368636-A1 NOVEL HETEROCYCLIC COMPOUND, SALT THEREOF, AND LUMINESCENT SUBSTRATE COMPOSITION OXSR1, RER1, NR2E3 CCNE1 1244/4885CDK2 2571/4885CDK5 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.